670 related articles for article (PubMed ID: 15017504)
21. A controlled trial comparing ciprofloxacin with mesalazine for the treatment of active Crohn's disease. Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives (GETAID).
Colombel JF; Lémann M; Cassagnou M; Bouhnik Y; Duclos B; Dupas JL; Notteghem B; Mary JY
Am J Gastroenterol; 1999 Mar; 94(3):674-8. PubMed ID: 10086650
[TBL] [Abstract][Full Text] [Related]
22. Mesalamine once daily is more effective than twice daily in patients with quiescent ulcerative colitis.
Dignass AU; Bokemeyer B; Adamek H; Mross M; Vinter-Jensen L; Börner N; Silvennoinen J; Tan G; Pool MO; Stijnen T; Dietel P; Klugmann T; Vermeire S; Bhatt A; Veerman H
Clin Gastroenterol Hepatol; 2009 Jul; 7(7):762-9. PubMed ID: 19375519
[TBL] [Abstract][Full Text] [Related]
23. Randomized clinical trial of Plantago ovata seeds (dietary fiber) as compared with mesalamine in maintaining remission in ulcerative colitis. Spanish Group for the Study of Crohn's Disease and Ulcerative Colitis (GETECCU).
Fernández-Bañares F; Hinojosa J; Sánchez-Lombraña JL; Navarro E; Martínez-Salmerón JF; García-Pugés A; González-Huix F; Riera J; González-Lara V; Domínguez-Abascal F; Giné JJ; Moles J; Gomollón F; Gassull MA
Am J Gastroenterol; 1999 Feb; 94(2):427-33. PubMed ID: 10022641
[TBL] [Abstract][Full Text] [Related]
24. Steroid-unresponsive acute attacks of inflammatory bowel disease: immunomodulation by tacrolimus (FK506).
Fellermann K; Ludwig D; Stahl M; David-Walek T; Stange EF
Am J Gastroenterol; 1998 Oct; 93(10):1860-6. PubMed ID: 9772045
[TBL] [Abstract][Full Text] [Related]
25. 6-tioguanine monitoring in steroid-dependent patients with inflammatory bowel diseases receiving azathioprine.
Roblin X; Serre-Debeauvais F; Phelip JM; Faucheron JL; Hardy G; Chartier A; Helluwaert F; Bessard G; Bonaz B
Aliment Pharmacol Ther; 2005 Apr; 21(7):829-39. PubMed ID: 15801918
[TBL] [Abstract][Full Text] [Related]
26. [Maintenance treatment of Crohn's disease using orally administered mesalazine (Pentasa). A controlled multicenter study. The Study Groups on the Treatment of Inflammatory Digestive Disorders].
Gendre JP; Mary JY; Florent C; Modigliani R; Colombel JF; Soulé JC; Galmiche JP; Lerebours E; Descos L; Viteau JM
Ann Gastroenterol Hepatol (Paris); 1993 Oct; 29(5):251-6. PubMed ID: 8250520
[TBL] [Abstract][Full Text] [Related]
27. [Compared azathioprine efficacy in ulcerative colitis and in Crohn's disease].
Kull E; Beau P
Gastroenterol Clin Biol; 2002 Apr; 26(4):367-71. PubMed ID: 12070412
[TBL] [Abstract][Full Text] [Related]
28. A multicenter, randomized, double-blind trial of everolimus versus azathioprine and placebo to maintain steroid-induced remission in patients with moderate-to-severe active Crohn's disease.
Reinisch W; Panés J; Lémann M; Schreiber S; Feagan B; Schmidt S; Sturniolo GC; Mikhailova T; Alexeeva O; Sanna L; Haas T; Korom S; Mayer H
Am J Gastroenterol; 2008 Sep; 103(9):2284-92. PubMed ID: 18671816
[TBL] [Abstract][Full Text] [Related]
29. Medical management of mild to moderate Crohn's disease: evidence-based treatment algorithms for induction and maintenance of remission.
Sandborn WJ; Feagan BG; Lichtenstein GR
Aliment Pharmacol Ther; 2007 Oct; 26(7):987-1003. PubMed ID: 17877506
[TBL] [Abstract][Full Text] [Related]
30. Review article: chronic active disease and maintaining remission in Crohn's disease.
Kamm MA
Aliment Pharmacol Ther; 2004 Oct; 20 Suppl 4():102-5. PubMed ID: 15352904
[TBL] [Abstract][Full Text] [Related]
31. Low-dose cyclosporine for the treatment of Crohn's disease. The Canadian Crohn's Relapse Prevention Trial Investigators.
Feagan BG; McDonald JW; Rochon J; Laupacis A; Fedorak RN; Kinnear D; Saibil F; Groll A; Archambault A; Gillies R
N Engl J Med; 1994 Jun; 330(26):1846-51. PubMed ID: 8196727
[TBL] [Abstract][Full Text] [Related]
32. Aminosalicylates for induction of remission or response in Crohn's disease.
Lim WC; Hanauer S
Cochrane Database Syst Rev; 2010 Dec; (12):CD008870. PubMed ID: 21154400
[TBL] [Abstract][Full Text] [Related]
33. Beclomethasone dipropionate versus mesalazine in distal ulcerative colitis: a multicenter, randomized, double-blind study.
Biancone L; Gionchetti P; Blanco Gdel V; Orlando A; Annese V; Papi C; Sostegni R; D'Incà R; Petruzziello C; Casa A; Sica G; Calabrese E; Campieri M; Pallone F
Dig Liver Dis; 2007 Apr; 39(4):329-37. PubMed ID: 17347061
[TBL] [Abstract][Full Text] [Related]
34. Granulocyteaphaeresis in steroid-dependent inflammatory bowel disease: a prospective, open, pilot study.
Domènech E; Hinojosa J; Esteve-Comas M; Gomollón F; Herrera JM; Bastida G; Obrador A; Ruiz R; Saro C; Gassull MA;
Aliment Pharmacol Ther; 2004 Dec; 20(11-12):1347-52. PubMed ID: 15606397
[TBL] [Abstract][Full Text] [Related]
35. High-dose intravenous cyclosporine in steroid refractory attacks of inflammatory bowel disease.
Hermida-Rodriguez C; Cantero Perona J; Garcia-Valriberas R; Pajares Garcia JM; Mate-Jimenez J
Hepatogastroenterology; 1999; 46(28):2265-8. PubMed ID: 10521978
[TBL] [Abstract][Full Text] [Related]
36. Azathioprine is superior to budesonide in achieving and maintaining mucosal healing and histologic remission in steroid-dependent Crohn's disease.
Mantzaris GJ; Christidou A; Sfakianakis M; Roussos A; Koilakou S; Petraki K; Polyzou P
Inflamm Bowel Dis; 2009 Mar; 15(3):375-82. PubMed ID: 19009634
[TBL] [Abstract][Full Text] [Related]
37. Prevention of relapse by mesalazine (Pentasa) in pediatric Crohn's disease: a multicenter, double-blind, randomized, placebo-controlled trial.
Cezard JP; Munck A; Mouterde O; Morali A; Lenaerts C; Lachaux A; Turck D; Schmitz J; Maurage C; Girardet JP; Belli D; Lamireau T; Sarles J; Chouraqui JP; Descos B; Dabadi A; Meyer M; Olives JP; Mary JY
Gastroenterol Clin Biol; 2009 Jan; 33(1 Pt 1):31-40. PubMed ID: 19118966
[TBL] [Abstract][Full Text] [Related]
38. Budesonide is more effective than mesalamine or placebo in short-term treatment of collagenous colitis.
Miehlke S; Madisch A; Kupcinskas L; Petrauskas D; Böhm G; Marks HJ; Neumeyer M; Nathan T; Fernández-Bañares F; Greinwald R; Mohrbacher R; Vieth M; Bonderup OK;
Gastroenterology; 2014 May; 146(5):1222-30.e1-2. PubMed ID: 24440672
[TBL] [Abstract][Full Text] [Related]
39. Coated oral 5-aminosalicylic acid versus placebo in maintaining remission of inactive Crohn's disease. International Mesalazine Study Group.
Aliment Pharmacol Ther; 1990 Feb; 4(1):55-64. PubMed ID: 2104074
[TBL] [Abstract][Full Text] [Related]
40. Current treatment for prevention of relapse and recurrence in Crohn's disease.
Prantera C; Scribano ML
Ital J Gastroenterol Hepatol; 1999; 31(6):515-8. PubMed ID: 10575572
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
